— Early sign of Alzheimer's reversed in lab — One of the earliest known impairments caused by Alzheimer's disease - loss of sense of smell - can be restored by removing a plaque-forming protein in a mouse model of the disease,…
— Parental controls on embryonic development? — When a sperm fertilises an egg, each contributes a set of chromosomes to the resulting embryo, which at these very early stages is called a zygote. Early on, zygotic genes are inert,…
— Newly discovered heart stem cells make muscle and bone — Researchers have identified a new and relatively abundant pool of stem cells in the heart. The findings in the December issue of Cell Stem Cell, a Cell Press publication, show that…
— BUSM researchers develop blood test to detect membranous nephropathy — Research conducted by a pair of physicians at Boston University School of Medicine (BUSM) and Boston Medical Centre (BMC) has led to the development of a test that can help diagnose…
— New hip implants no better than traditional implants — New hip implants appear to have no advantage over traditional implants, suggests a review of the evidence published on bmj.com today…
— Action needed to improve men's health in Europe — Policies aimed specifically at men are urgently needed to improve the health of Europe's men, say experts on bmj.com today…
— Probiotics reduce infections for patients in intensive care — Traumatic brain injury is associated with a profound suppression of the patient's ability to fight infection. At the same time the patient also often suffers hyper-inflammation, due…
— High blood sugar levels in older women linked to colorectal cancer — Elevated blood sugar levels are associated with an increased risk of colorectal cancer, according to a study led by researchers at Albert Einstein College of Medicine of Yeshiva University.…
— Engineered botulism toxins could have broader role in medicine — The most poisonous substance on Earth - already used medically in small doses to treat certain nerve disorders and facial wrinkles - could be re-engineered for an expanded role in helping…
Combination therapy targets stubborn leukaemia stem cells
New research discovers a combination of drugs that may prove to be a more effective treatment for a lethal form of leukaemia. The study, published by Cell Press in the May issue of the journal Cancer Cell, reports that the new therapeutic strategy effectively targets notoriously intractable leukaemia stem cells that often escape standard treatment and are a main factor in disease relapse.
Chronic myelogenous leukaemia (CML) is a deadly form of leukaemia that is associated with chromosome rearrangements that result in the expression of the BCR-ABL oncoprotein. 'Treatment of CML with the BCL-ABL inhibitor imatinib mesylate (IM, Gleevec) has emerged as the first-line treatment for patients with CML,' explains senior study author Dr Ravi Bhatia, the director of Stem Cell and Leukemia Research at the City of Hope National Medical Centre in Duarte, California. 'However, although most CML patients initially respond well to IM treatment, there is evidence that primitive quiescent leukaemia stem cells are retained in patients achieving remission after IM treatment and that these stem cells are responsible for disease recurrence.'
Dr Bhatia and colleagues were interested in examining whether histone deacetylase inhibitors (HDACi) that have shown some promise as a treatment for several other cancers, might be effective at eliminating CML stem cells. HDACi were of interest because they not only target rapidly dividing cancer cells but also have been shown to eliminate non-proliferating cancer cells. The researchers found that treatment with a combination of HDACi and IM effectively reduced CML cells that were resistant to IM alone. Further, a combination of HDACi and IM markedly diminished leukaemia stem cells in a mouse model of CML.
The group went on to show that the interaction of HDACi and IM inhibited genes involved in regulating leukaemia stem cell survival. 'Our studies indicate that treatment with HDACi combined with IM is effective against CML leukaemia stem cells that resist elimination by IM alone,' concludes Dr Bhatia. 'Several HDACi are in clinical development, and our studies support clinical trials of HDACi in combination with tyrosine kinase inhibitors to eliminate leukaemia stem cells in patients with CML.'
Or subscribe for our Newsletter, a free e-mail publication. It is published practically every day.
New stretchable electrodes created to study stresses on cardiac cells
Scientists unlock molecular origin of blood stem cells
Protein's essential role in repairing damaged cells revealed
Researchers at the Salk Institute develop novel glioblastoma mouse model